Arcutis Biotherapeutics (ARQT) Wins FDA Filing Acceptance For ZORYVE, Is The Discount Still Justified?
The recent move in Arcutis Biotherapeutics (ARQT) comes after the FDA accepted a supplemental application for ZORYVE cream 0.05%, which could extend its use to infants with mild to moderate atopic dermatitis.
See our latest analysis for Arcutis Biotherapeutics.
Against this backdrop, Arcutis Biotherapeutics’ recent 1-month share price return of 8.66% and 90-day share price return of 16.14% suggest improving momentum, while the year-to-date share price return has slightly declined 1.76%. Over the same period, the 1-year total shareholder return of 94.21% and 3-year total shareholder return of 171.59% point to a much stronger longer term picture as the market reacts to progress with ZORYVE and recent board changes.
If this kind of specialty healthcare story interests you, it may be worth widening your search to other dermatology and healthcare AI opportunities using our dedicated screener for 39 healthcare AI stocks
Arcutis Biotherapeutics now trades at a steep intrinsic discount and sits more than 20% below the average analyst target, even after the recent ZORYVE driven move. Is the market’s caution on this dermatology specialist overdone or well placed?
Most Popular Narrative: 17.7% Undervalued
Arcutis Biotherapeutics closed at $28.49, while the most followed narrative anchors fair value at $34.63, framing the current price as a discount to its long run potential under that view.
Arcutis is poised to sustain and accelerate top-line revenue growth through continued expansion of ZORYVE indications, targeting large, underserved populations such as pediatric atopic dermatitis and scalp psoriasis, while leveraging broadening insurance coverage and the ongoing shift away from steroid use in chronic dermatologic conditions.
The fair value story here leans heavily on rapid revenue compounding, a sharp swing from current losses to healthy margins, and a premium future earnings multiple. Curious which assumptions matter most and how ambitious they really are? The full narrative spells out the revenue ramp, margin shift and valuation bridge that underpin that $34.63 figure.
Result: Fair Value of $34.63 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Arcutis Biotherapeutics still faces concentration on the ZORYVE franchise and evolving payer dynamics, either of which could challenge the current fair value narrative.
Find out about the key risks to this Arcutis Biotherapeutics narrative.
Next Steps
If the story around Arcutis Biotherapeutics so far feels optimistic but uncertain, consider acting promptly by stress testing the narrative against your own expectations and risk tolerance, then reviewing the 5 key rewards
Looking for more investment ideas beyond Arcutis Biotherapeutics?
Do not stop with Arcutis Biotherapeutics. Broaden your watchlist with fresh ideas that match your goals, risk comfort and time horizon using targeted screeners.
- Target potential value opportunities before they are widely followed by reviewing the screener containing 20 high quality undiscovered gems.
- Focus on financial strength first by scanning the solid balance sheet and fundamentals stocks screener (47 results).
- Prioritise stability and sleep better at night by checking companies in the 84 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com